This feature appears to be linked to swift commercialization: we observed entry for 86% of generics eligible for CGT X, with a median time-to-market of 2.5 days (1 day excluding complex products). Neat implications for the design of provisions to increase drug competition.
📢 New work with @US_FDA colleagues 📢
We looked at products that used the Competitive Generic Therapy (CGT) pathway to come to market. CGT includes designation and possible exclusivity, but it's not your typical 180-day exclusivity. CGT exclusivity is use it or lose it.
Study describes the characteristics and outcomes of products that have sought Competitive Generic Therapy designation and exclusivity https://t.co/t0h8uLt4mH
Our next #RegSci2021 Early Career Seminar on April 29th features recent @Harvard@HMSHCP health economics PhD graduate and current Public Health and Regulatory Research Fellow at @US_FDA, Dr. @AbelleFowler!
RSVP here: https://t.co/736vBzXsAd
Our research on public opinions about gender equality across 17 countries is out! It is a privilege to have been part of the team that lead this work at @WomenDeliver alongside @_Focus2030. Follow the link to explore the findings: https://t.co/qCOwR9K8VL https://t.co/M8NqZvQwYS
I'm happy to announce that I defended my dissertation last week! I'm grateful to my dream team committee: Tom McGuire, @Cutler_econ, @JMichaelMcW and @arieldora. Next up: starting as an ORISE Fellow in the Office of the @FDACommissioner, @US_FDA. Can't wait!
@walidgellad Gilead's Chairman and CEO walked back that press release in this letter. It's irresponsible to make those claims and they know it. https://t.co/Neab1ifnlK.
Some thoughts on how #COVID19 may affect the readiness of the U.S. armed forces with my @MIT_SSP teammate @racheltecott in @monkeycageblog / @washingtonpost.
Thanks for the shoutout, @ashecon!
A new version of my JMP is up, reflecting awesome comments I've received over the past few weeks: https://t.co/q8JcaEmtpH
And of course, big thanks to my outstanding committee @arieldora@JMichaelMcW @Cutler_econ and Tom McGuire
Nice presentation from @AbelleFowler@harvardmed@HMSHCP on her new paper Hurry Up or Wait?: Strategic Delay in the Introduction of Pharmaceutical Line Extensions!
Nice presentation from @AbelleFowler@harvardmed@HMSHCP on her new paper Hurry Up or Wait?: Strategic Delay in the Introduction of Pharmaceutical Line Extensions!
PhD students, are you on the job market? Then join us for the webinar "Strategies (and Encouragement) for Ph.D. Health Economists on the Job Market" with @cawley_john on December 4th from 12pm-1:30pm EST! Sign-up here: https://t.co/OlVxVQCXat #econtwitter#economics#healthecon
It's always a special day when one of @middecon's own returns to present her own research. In this case, @AbelleFowler, who is on the market this winter from the Health Policy program at Harvard, presented work on pharma line extensions:
https://t.co/QsFldrwfOL
(Hire her!)